Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
“Differentiating among hereditary anemias is extremely challenging, given the wide range of disorders and unspecified or overlapping phenotypes. Having a specific diagnosis is extremely helpful, allowing us to tailor the treatment and management approach to the particular anemia,” said Dr.
“We launched the Anemia ID program as a result of our continuing commitment to the hematology communities we serve,” said
Agios launched the Anemia ID program, in partnership with PerkinElmer Genomics, in response to feedback from patients, advocates and physicians about the need for improved diagnosis to inform disease management decisions. Agios plans to work with physicians across the country to educate about the availability of the test. Participating physicians will order a test kit from PerkinElmer Genomics, collect a single blood or saliva sample from the patient and return the kit to PerkinElmer Genomics, which will perform the molecular analysis and provide the clinical interpretation. While genetic testing alone cannot provide a definitive diagnosis, it is used in conjunction with additional clinical data or testing to diagnose the underlying cause of the patient’s anemia. Eligible patients will receive the Anemia ID genetic test at no cost, subject to the program’s terms and conditions.
About Anemia ID
The goal of the Anemia ID program is to provide a diagnosis confirming the underlying cause(s) of a patient’s hereditary anemia, support the development of an effective management plan, inform genetic counseling discussions and enable the identification of appropriate treatment options or clinical trials. The next-generation sequencing panel uses a single blood or saliva sample to test for more than 50 mutated genes and disorders, including congenital dyserythropoietic anemias, Diamond-Blackfan anemia, enzymopathies (red blood cell enzyme disorders) including pyruvate kinase deficiency, membranopathies (red blood cell membrane disorders) and other disorders with overlapping clinical features.
All testing provided to patients through Anemia ID is paid for by
To learn more about the program, please visit www.AnemiaID.com.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of the Anemia ID program; and the benefit of Agios’ strategic plans and focus. The words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook," "goal", "potential" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, a positive opinion on Agios’ application for orphan drug designation for mitapivat is not a guarantee of approval. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: risks and uncertainties related to the impact of the COVID-19 pandemic to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; the results of Agios’ clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients and conduct its current and future clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations; and general economic, market and global health conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios’ public filings with the
Contacts
Investors:
Director, Investor Relations
Holly.Manning@agios.com
Media:
Associate Director, Corporate Communications
Jessica.Rennekamp@agios.com
Source: Agios Pharmaceuticals, Inc.
